Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 38 points (0.2%) at 16,171 as of Friday, Feb. 21, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,939 issues advancing vs. 967 declining with 167 unchanged. The Drugs industry currently sits up 1.2% versus the S&P 500, which is up 0.3%. On the negative front, top decliners within the industry include Actavis ( ACT), down 1.7%, and Allergan ( AGN), down 1.1%. Top gainers within the industry include Isis Pharmaceuticals ( ISIS), up 17.1%, Biogen Idec ( BIIB), up 3.9%, Regeneron Pharmaceuticals ( REGN), up 3.1%, Alexion Pharmaceuticals ( ALXN), up 1.9% and Amgen ( AMGN), up 1.2%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Hospira ( HSP) is one of the companies pushing the Drugs industry lower today. As of noon trading, Hospira is down $2.02 (-4.6%) to $41.96 on heavy volume. Thus far, 1.2 million shares of Hospira exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $41.88-$43.90 after having opened the day at $43.90 as compared to the previous trading day's close of $43.98. Hospira, Inc. provides injectable drugs and infusion technologies to develop, manufacture, distribute, and markets products worldwide. Hospira has a market cap of $7.3 billion and is part of the health care sector. Shares are up 6.1% year-to-date as of the close of trading on Thursday. Currently there are no analysts that rate Hospira a buy, 1 analyst rates it a sell, and 7 rate it a hold. TheStreet Ratings rates Hospira as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full Hospira Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.